The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Targeting anoikis resistance in prostate cancer metastasis
Open accessAbstract
Anoikis is a mode of apoptotic cell death, consequential to insufficient cell-matrix interactions and a critical player in tumor angiogenesis and metastasis. The events involved in tumor cell progression toward metastasis potential are mediated by integrins, which upon engagement with components of the extracellular matrix (ECM), reorganize to form adhesion complexes. Targeting apoptotic players is of immense therapeutic significance since resistance to apoptosis is not only critical in conferring therapeutic failure to standard treatment strategies, but anoikis (apoptosis upon loss of anchorage and detachment from ECM also plays an important role in angiogenesis and metastasis. The ability to survive in the absence of adhesion to the ECM, enables tumor cells to disseminate from the primary tumor site, invade a distant site and establish a metastatic lesion. Tumor cells can escape from detachment-induced apoptosis by controlling anoikis pathways, including the extrinsic death receptor pathway and the ECM-integrin mediated cell survival pathway. Considering the functional promiscuity of individual signaling effectors, it is critical to dissect the molecular networks mechanistically driving tumor cells to evade anoikis and embark on a metastatic spread. Resistance to die via anoikis dictates tumor cell survival and provides a molecular basis for therapeutic targeting of metastatic prostate cancer. Further dissection of critical anoikis signaling events will enable the therapeutic optimization of anoikis targeting to impair prostate cancer metastasis prior to its initiation. This review will discuss the molecular understanding of anoikis regulation in the tumor microenvironment and the in vivo pharmacological implementation of a novel class of antitumor-drugs to optimize apoptotic-based therapeutic targeting, bypassing anoikis-resistance to impair prostate cancer progression to metastasis. Potential combination strategies targeting tumor vascularity (via anoikis) and impairing tumor initiation (via “classic” apoptosis), provide strong therapeutic promise for metastatic prostate cancer by preventing the onset of metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Giancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Breast cancer metastasis: markers and models
Weigelt, B., Peterse, J. L., & van't Veer, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1670 · Cited by 2,232
Frisch, S. M., & Screaton, R. A. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00251-9 · Cited by 1,249
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109
Enders, A., Bouillet, P., Puthalakath, H., Xu, Y., Tarlinton, D. M., & Strasser, A. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030411 · Cited by 295
Cited by
Tryptophan metabolism in health and disease
Xue, C., Li, G., Zheng, Q., Gu, X., Shi, Q., Su, Y., Chu, Q., Yuan, X., Bao, Z., Lu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.004 · Cited by 961
Cancer metastases: challenges and opportunities
Guan, X. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.07.005 · Cited by 952
Bourboulia, D., & Stetler-Stevenson, W. G. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.05.002 · Cited by 710
Anoikis: an emerging hallmark in health and diseases
Taddei, M., Giannoni, E., Fiaschi, T., & Chiarugi, P. (2012) · The Journal of Pathology · doi:10.1002/path.3000 · Cited by 716
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Bergamo, A., & Sava, G. (2011) · Dalton Transactions · doi:10.1039/c0dt01816c · Cited by 440
Metadata
- Authors
- Sakamoto, S., & Kyprianou, N.
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 31
- Issue
- 2
- Pages
- 205-214
- ISSN
- 0098-2997 (ISSN-L)
- OpenAlex
- W2080064317
- Cited by
- 180
- References
- 7
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting anoikis resistance in prostate cancer metastasis. https://app.cochat.ai/papers/10.1016/j.mam.2010.02.001
- The paper
- Sakamoto, S., & Kyprianou, N. (2010). Targeting anoikis resistance in prostate cancer metastasis. Molecular Aspects of Medicine. https://doi.org/10.1016/j.mam.2010.02.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.